Your browser doesn't support javascript.
loading
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective.
Bagepally, Bhavani Shankara; Chaikledkaew, Usa; Youngkong, Sitaporn; Anothaisintawee, Thunyarat; Thavorncharoensap, Montarat; Dejthevaporn, Charungthai; Thakkinstian, Ammarin.
Afiliação
  • Bagepally BS; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Chaikledkaew U; Department of Non-Communicable Diseases, ICMR-National Institute of Epidemiology, Chennai, India.
  • Youngkong S; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Anothaisintawee T; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Thavorncharoensap M; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
  • Dejthevaporn C; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Thakkinstian A; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.
Clinicoecon Outcomes Res ; 13: 897-907, 2021.
Article em En | MEDLINE | ID: mdl-34712053
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2021 Tipo de documento: Article